The present invention relates to novel amyloid binding compounds of formula (I) and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the compounds of this invention as tracers in positron emission tomography (PET/) imaging to study amyloid deposits in brain in vivo to allow diagnosis of Alzheimer's disease. Thus, the present invention relates to use of the novel amyloid binding compounds as a diagnostic. The invention further relates to a method of measuring clinical efficacy of Alzheimer's disease therapeutic agents. Specifically, the present invention relates to novel aryl or heteroaryl substituted azabenzoxazole derivatives, compositions, and therapeutic uses and processes for making such compounds, or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein: X is O or S; A and Y independently are N, or CH.
本发明涉及公式(I)的新型淀粉样结合化合物以及通过测量活体患者淀粉样斑块
水平的变化来测量化合物效果的方法。更具体地说,本发明涉及使用本发明中的化合物作为正电子发射断层扫描(PET)成像中的示踪剂来研究体内脑部淀粉样沉积物,以允许诊断阿尔茨海默病的方法。因此,本发明涉及将新型淀粉样结合化合物用作诊断工具。本发明还涉及测量阿尔茨海默病治疗剂临床疗效的方法。具体而言,本发明涉及新型芳基或杂环芳基取代的氮杂苯并
噁唑衍
生物、组成物和治疗用途以及制备这种化合物的过程,或其药学上可接受的盐、溶剂合物或体内可
水解的酯。其中:X为O或S;A和Y分别为N或CH。